3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Terminated
2
Completed
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
3
Conditions
Breast Neoplasms
106
Neoplasms
14
Neoplasm Metastasis
14
Carcinoma, Non-Small-Cell Lung
4
Advanced Breast Cancer
4
Hereditary Sensory and Autonomic Neuropathies
3
Recurrence
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Multiple Endocrine Neoplasia Type 1
2
Endometrial Neoplasms
2
Breast Neoplasms, Male
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Solid Malignancies
1
Recurrent Uterine Corpus Carcinoma
1
Neoplasms by Site
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Lethal Congenital Contracture Syndrome 2
1
Hyperglycemia
1
Hormone Receptor Positive HER-2 Negative Breast Cancer
1
Hormone Receptor Positive Breast Cancer
1
HER2-positive Breast Cancer
1
Female Breast Carcinoma
1
Exanthema
1
Interventions
Alpelisib
4
berzosertib
3
Fulvestrant
3
Everolimus
3
parsaclisib
2
Topotecan
2
NVP-BKM120
2
Cetuximab
2
talazoparib
1
sotorasib
1
serabelisib
1
ruxolitinib
1
duvelisib
1
dapagliflozin
1
cobimetinib
1
ceralasertib
1
binimetinib
1
avelumab
1
Vemurafenib
1
SF 1126
1
Rituximab
1
Paclitaxel
1
Oxaliplatin
1
Leuprolide
1
Leucovorin
1
Letrozole
1
Irinotecan
1
Goserelin
1
Fluorouracil
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Has results
×
Hereditary Sensory and Autonomic Neuropathies
×
Fulvestrant
×
Clear all
NCT03056755
2026-01-13
BYLieve
Novartis
Phase 2
Completed
383 enrolled
16 charts
NCT04899349
2024-10-09
EPIK-B4
Novartis
Phase 2
Terminated
2 enrolled
8 charts
NCT01633060
2019-01-30
BELLE-3
Novartis
Phase 3
Terminated
432 enrolled
20 charts